12. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, rando...
近日,山东大学材料学院蒋妍彦团队在Advanced Science(IF=16.8 一区)杂志上发表了题为:“A Multifunctional Bimetallic Nanoplatform for Synergic Local Hyperthermia and Chemotherapy Targeting HER2-Positive Breast Cancer.”的文章,研究团队开发了一个纳米治疗平台,结合了双金属金银空心纳米壳、吡咯替尼和赫赛汀,实现了多...
[6]Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(97...
the peony phase 3 randomized clinical trial. jama oncol. 2020;6(3):e193692. doi:10.1001/jamaoncol.2019.3692 3.hurvitz sa, martin m, symmans wf, et al. neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab...
[5] Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(33):3744–3752. ...
Cancer Lett. 430, 47–56 (2018). 11. Varadan, V. et al. Immune signatures following single dose trastuzumab predict pathologic response to preoperative trastuzumab and chemotherapy in HER2-positive early breast cancer. Clin. Cancer Res. 22, 3249–3259 (2016). 12. Triulzi, T. et al. HER2...
[1] Edith, et al., Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology, 2014. 32(33). ...
5. van Ramshorst MS, van der Voort A, van Werkhoven ED, et al: Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 19:1630-1640, 2018 ...
[10]、Fleur Louis,et al.“RF1-03:Three-year event-free survival(EFS)of the multicenter phase II TRAIN-3 study evaluating image-guided optimization of neoadjuvant chemotherapy duration in stage II and III HER2-positive breast cancer(BOOG 2018-01).”2024 SABCS Abstract.RF1-03. [11]、Tolaney...
1. Hurvitz S A, Martin M, Symmans W F, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial[J]. The Lancet Oncology, 2018, 19(1...